What is a PROTAC and how does targeted protein degradation work?

Traditional drug inhibition: conventional small molecule drugs bind to a protein's active site, blocking the protein's function; the drug is typically competitive with the natural substrate; when the drug leaves the binding site (drug wears off), the protein function returns; if the protein mutates at the binding site, resistance develops. PROTAC mechanism: a PROTAC (PROteolysis-TArgeting Chimera) is a bifunctional molecule with three components: a ligand for the target protein (which binds the disease-causing protein), a linker connecting the two ligands, and a ligand for an E3 ubiquitin ligase (a cellular enzyme that tags proteins for destruction by the proteasome, the cell's protein-disposal machinery); when the PROTAC binds both the target protein and an E3 ligase simultaneously, it creates a complex that causes the E3 ligase to attach ubiquitin tags to the target protein; ubiquitinated proteins are recognized by the proteasome and destroyed. Catalytic degradation: unlike conventional inhibitors (which occupy the target protein continuously), a PROTAC is catalytic — after the target protein is ubiquitinated and degraded, the PROTAC is released and can engage another target protein molecule; one PROTAC molecule can degrade many copies of the target protein; this catalytic mode of action may provide superior efficacy at lower drug concentrations. Advantages over inhibition: PROTACs degrade the entire protein, eliminating both catalytic and scaffolding functions; proteins with scaffold roles (like IRAK4's role in signaling complexes independent of its kinase activity) are resistant to kinase inhibitors but susceptible to degradation; proteins with binding site mutations that resist inhibitors are still degraded by PROTACs that bind a different surface; this potentially addresses drug resistance.

What is IRAK4 and why is it a target in inflammatory diseases?

IRAK4 biology: IRAK4 (Interleukin-1 Receptor-Associated Kinase 4) is a kinase protein that plays a central role in innate immune signaling — it is activated downstream of Toll-like receptors (TLRs) and IL-1 family receptors (like IL-1R, IL-18R, IL-33R); when pathogens activate TLRs, IRAK4 is recruited to the signaling complex and phosphorylates downstream proteins that activate NF-kappaB and other inflammatory transcription factors; this drives production of inflammatory cytokines (IL-6, TNF-alpha, IL-8) that cause inflammation. Role in inflammatory diseases: in autoimmune diseases (atopic dermatitis, hidradenitis suppurativa, rheumatoid arthritis, psoriasis), TLR and IL-1 receptor signaling is hyperactivated; inhibiting or eliminating IRAK4 reduces excessive inflammatory cytokine production; clinical trials with IRAK4 inhibitors have shown efficacy in atopic dermatitis and other inflammatory conditions. Why degradation may be better than inhibition: IRAK4 has both kinase (enzymatic) functions and scaffolding functions; the scaffolding role involves IRAK4 participating in signaling complexes (MyD88-IRAK4-IRAK1/2 complex) independently of its kinase activity; kinase inhibitors block the kinase function but leave the scaffold intact, allowing some signaling to continue; degrading IRAK4 eliminates both functions completely, potentially providing superior efficacy vs. pure kinase inhibition; Kymera believes this is why degradation may outperform inhibition for IRAK4.

What clinical data are investors looking for from RVMD and KYMR?

Revolution Medicines clinical milestones: RMC-6236 (RAS(ON) multi-selective) Phase 1b/2 data — investors want objective response rate (ORR: percentage of patients whose tumors shrink by >30%), disease control rate (DCR: ORR plus stable disease), and duration of response; particularly critical is pancreatic cancer data (KRASG12D mutations, no approved KRAS therapies) and NSCLC data; safety data on drug-related adverse events; combination data (RMC-6236 plus other agents) showing whether combinations improve ORR or prevent resistance. Clinical readout timeline: biotechs provide data at major oncology conferences (ASCO, ESMO, AACR); positive data (high ORR in a difficult cancer) can drive stock up 30-100%+; negative data (low ORR or safety concerns) can cause 50-80%+ stock declines; this binary outcome characteristic is what makes clinical-stage biotech investing high-risk. Kymera clinical milestones: KT-474 (IRAK4 degrader) Phase 2 data in atopic dermatitis — investors look for improvement in EASI score (Eczema Area and Severity Index) vs. placebo; STAT3 degrader Phase 1 data in T-cell lymphomas — safety and preliminary efficacy signals; the key comparison is vs. approved atopic dermatitis treatments (dupilumab/Dupixent by Regeneron is the gold standard). General biotech investing principle: clinical-stage biotech is essentially venture investing in public markets — investors bear the risk of clinical failure but potentially get much greater liquidity than private biotech investing; diversification across multiple clinical-stage biotechs reduces the catastrophic risk of any single program failing; most individual clinical programs fail (60-70% failure rate across Phase 2); successful programs in unmet needs with strong Phase 2 data often get acquired by large pharma companies at substantial premiums.

Last updated: August 4, 2026

brimindinvest.com / compare / rvmd-vs-kymrLIVE

RVMD

Revolution Medicines, Inc. · Healthcare - Clinical-Stage Oncology Biotech

$187.53

+0.01% this month

VERSUS

⟷

COMPARE

KYMR

Kymera Therapeutics, Inc. · Healthcare - Clinical-Stage Biotech (Targeted Protein Degradation)

$103.40

-9.46% this month

Scoreboard verdict

Across AI score, momentum, valuation, upside, operating margin

RVMD

2

KYMR

2

MIXED SETUP

Comparison scoreboard

MIXED SETUP

AI Score

RVMD ✓48.2

KYMR 47.3

1Y Return

RVMD ✓+403.17%

KYMR +136.34%

Fwd P/E

RVMD -31.45

KYMR ✓-23.03

Target Up.

RVMD +13.46%

KYMR ✓+26.79%

Op. Margin

RVMD N/A

KYMR N/A

Metrics last refreshed: 8/4/2026

Quick take

RVMD vs KYMR Stock Comparison: AI Score, Valuation, Performance and Upside

RVMD (Revolution Medicines) and KYMR (Kymera Therapeutics) are both clinical-stage oncology/immunology biotechs pursuing next-generation drug modalities against previously undruggable targets — Revolution Medicines targets the RAS oncogene 'ON-state' in cancer with RAS(ON) inhibitors for pancreatic and lung cancer, while Kymera Therapeutics uses PROTAC targeted protein degradation to eliminate IRAK4 (in inflammatory diseases) and STAT3 (in cancers).

RVMD vs KYMR is RAS pathway oncology pioneer targeting previously undruggable KRAS mutations in pancreatic and lung cancer (Revolution Medicines' RAS(ON) multi-selective inhibitors, significant clinical excitement around RMC-6236, and combination potential as a backbone — binary clinical stage risk against intensifying KRAS competitive landscape) versus targeted protein degradation technology platform applying PROTAC technology to oncology and inflammatory disease (Kymera's IRAK4 degrader inflammatory disease potential, STAT3 oncology degrader, and platform breadth — managing PROTAC drug delivery challenges and competitive pressure from multiple large pharma degrader programs).

Live analysis · updated 8/4/2026

RVMD and KYMR are closely matched — they split the tracked metrics evenly. RVMD has delivered stronger 1-year price return (+403.17% vs +136.34%), though KYMR has the better forward P/E setup (-23.03x vs -31.45x for RVMD). Analyst consensus implies meaningfully more upside for KYMR (+26.79%) than for RVMD (+13.46%).

Normalized 1Y performance

RVMD

KYMR

Recent returns

RVMD

KYMR

Analyst price targets & sentiment

RVMD · 21 analysts

STRONG BUYHOLDSTRONG SELL

Strong Buy (1.3/5.0)

Price target range

analyst low$151.00
analyst high$263.00
analyst mean$207.00
current price$187.53

+13.5% upside to analyst mean

KYMR · 22 analysts

STRONG BUYHOLDSTRONG SELL

Strong Buy (1.4/5.0)

Price target range

analyst low$97.00
analyst high$155.00
analyst mean$127.18
current price$103.40

+26.8% upside to analyst mean

Who should consider this stock?

RVMD may suit investors who:

→Want high-risk, high-reward exposure to the KRAS/RAS oncology space through a differentiated RAS(ON) approach that may provide superior activity in more RAS mutation types than approved KRAS(OFF) inhibitors
→Believe the massive unmet medical need in KRAS-mutant pancreatic cancer (one of the worst cancers with a 5-year survival below 15%) justifies the risk profile of a clinical-stage KRAS program
→See RMC-6236's early clinical excitement as evidence of genuine differentiation vs. approved KRAS inhibitors that supports continued investment despite the competitive landscape

KYMR may suit investors who:

→Want exposure to targeted protein degradation (PROTAC) technology as a potentially transformative new drug modality that expands the druggable proteome beyond what traditional inhibitors can target
→Believe IRAK4 degradation has best-in-class potential in atopic dermatitis and hidradenitis suppurativa by eliminating both kinase-dependent and scaffold signaling functions that inhibition cannot address
→Value Kymera's multi-therapeutic-area platform (oncology and immunology) as providing multiple shots at demonstrating TPD technology's clinical value across different disease settings

Performance & AI score

Performance & AI score
Metric	RVMD	KYMR
AI score	48.2	47.3
AI rank	#562	#602
Latest close	$187.53	$103.40
1M return	+0.01%	-9.46%
6M return	+90.97%	+39.90%
1Y return	+403.17%	+136.34%

$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

$10,000 invested — hypothetical growth (dividends reinvested)
Period	RVMD	KYMR
1Y ago	$50.32K (+403.2%) started 2025-07-31	$23.63K (+136.3%) started 2025-07-31
5Y ago	$63.92K (+539.2%) started 2021-08-02	$17.35K (+73.5%) started 2021-08-02
10Y ago	$64.89K (+548.9%) started 2020-02-13	$31.09K (+210.9%) started 2020-08-21

Hypothetical — past performance does not guarantee future results.

Valuation & upside potential

Valuation & upside potential
Metric	RVMD	KYMR
Market cap	$38.79B	$8.25B
Trailing P/E	N/A	N/A
Forward P/E	-31.45	-23.03
Price/Sales	3442.85	160.29
EV/Revenue	N/A	149.21
Analyst target	$207.00	$127.18
Target upside	+13.46%	+26.79%

Growth, profitability & risk

Growth, profitability & risk
Metric	RVMD	KYMR
Revenue growth	N/A	55.50%
Earnings growth	N/A	N/A
EPS growth	N/A	N/A
FCF margin	N/A	-270.54%
Operating margin	N/A	N/A
Profit margin	0.00%	0.00%
ROIC proxy	-76.67%	-27.09%
Return on equity	-76.67%	-27.09%
Dividend yield	0.00%	0.00%
Beta	1.40	1.95
Debt/equity	29.15	5.23
Current ratio	6.79	10.81
Quick ratio	6.59	10.39

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

RVMD max drawdown24.95%

KYMR max drawdown27.74%

RVMD max wkly drop18.71%

KYMR max wkly drop13.70%

5Y risk snapshot

RVMD max drawdown56.85%

KYMR max drawdown83.54%

RVMD max wkly drop46.20%

KYMR max wkly drop44.24%

10Y risk snapshot

RVMD max drawdown73.29%

KYMR max drawdown87.51%

RVMD max wkly drop46.20%

KYMR max wkly drop44.24%

Performance metrics by period

Performance metrics by period
Period	Metric	RVMD	KYMR
1Y	Growth	+403.17%	+136.34%
	CAGR	+403.72%	+136.48%
	Sharpe ratio	2.64	1.57
	Max drawdown	24.95%	27.74%
	Max daily drop	16.87%	9.15%
	Max wkly drop	18.71%	13.70%
5Y	Growth	+539.16%	+73.46%
	CAGR	+44.98%	+11.66%
	Sharpe ratio	0.83	0.44
	Max drawdown	56.85%	83.54%
	Max daily drop	34.38%	23.98%
	Max wkly drop	46.20%	44.24%
10Y	Growth	+548.89%	+210.88%
	CAGR	+33.57%	+21.04%
	Sharpe ratio	0.70	0.56
	Max drawdown	73.29%	87.51%
	Max daily drop	34.38%	23.98%
	Max wkly drop	46.20%	44.24%

Business comparison

Business comparison
Category	RVMD	KYMR
Company	Revolution Medicines, Inc.	Kymera Therapeutics, Inc.
Sector	Healthcare - Clinical-Stage Oncology Biotech	Healthcare - Clinical-Stage Biotech (Targeted Protein Degradation)
Industry	N/A	N/A
Core business	Revolution Medicines is a clinical-stage oncology company focused on RAS and RAS pathway cancers — cancers driven by mutations in RAS oncogenes (particularly KRAS, NRAS, and HRAS) that have historically been impossible to drug. Revolution's pipeline includes: RMC-6236 (RAS(ON) multi-selective inhibitor targeting multiple active RAS mutations), RMC-9805 (KRASG12D(ON) selective inhibitor targeting pancreatic cancer), and RMC-6291 (KRASG12C(ON) inhibitor). Revolution's approach — targeting the active (GTP-bound, 'ON') form of RAS rather than the inactive (GDP-bound, 'OFF') form targeted by Sotorasib (Amgen) and Adagrasib (Mirati/BMS) — may provide superior clinical activity. Revolution's lead program has generated significant clinical interest given the enormous unmet need in RAS-mutant cancers (pancreatic, lung, colorectal).	Kymera Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation (TPD) technology to eliminate disease-causing proteins rather than merely inhibiting them. Kymera's proprietary technology uses small molecules called PROTACs (Proteolysis Targeting Chimeras) that recruit cellular waste-disposal machinery (the ubiquitin-proteasome system) to destroy specific target proteins; because the PROTAC catalytically destroys multiple copies of the target protein rather than occupying its active site, PROTACs can potentially work against proteins that have developed resistance to traditional inhibitors. Kymera's pipeline includes degraders targeting IRAK4 (inflammation — atopic dermatitis and hidradenitis suppurativa), STAT3 (oncology), and IRAKimide (TYK2+IRAK4 degrader).
Investor focus	Investors track clinical trial data readouts (overall response rates, progression-free survival) for RVMD's RAS(ON) programs, competitive positioning vs. Amgen KRASG12C inhibitors, and potential for RMC-6236 as a backbone combination partner.	Investors track Kymera's clinical trial progress for its IRAK4 degraders in inflammatory diseases, STAT3 degrader early data, and the broader validation of the PROTAC/degrader technology platform.

RVMD strengths

→RAS oncogene targeting addresses the largest oncology market opportunity with previously undruggable mutations — KRAS is mutated in approximately 25-30% of all human cancers; KRAS mutations are drivers in pancreatic (90%), colorectal (40%), and non-small cell lung cancer (30%); until 2021 (Sotorasib approval), RAS was considered completely undruggable; Revolution's approach targets additional KRAS mutations beyond KRASG12C
→RAS(ON) inhibition strategy may provide broader and more durable activity than existing RAS(OFF) approaches — conventional KRASG12C inhibitors (Sotorasib, Adagrasib) work by trapping KRAS in the inactive 'OFF' state; Revolution's RAS(ON) approach targets the active state, which may provide activity in more tumor cell types and greater tumor regression
→Clinical data from RMC-6236 has generated significant excitement in the oncology community — early clinical results in KRAS-mutant cancers have shown strong activity signals that support continued clinical development

KYMR strengths

→Targeted protein degradation (TPD) is a potentially transformative new drug modality targeting previously undruggable proteins — traditional small molecule drugs must bind to a protein's active site; many disease-causing proteins lack accessible active sites (they are 'undruggable'); PROTACs/degraders can target a protein's surface without requiring active site binding, dramatically expanding the druggable proteome
→IRAK4 degrader has best-in-class potential in inflammatory diseases — Kymera's IRAK4 degrader (destroying IRAK4 protein rather than inhibiting it) may provide superior efficacy vs. IRAK4 inhibitors because complete protein elimination eliminates both kinase-dependent and scaffold signaling functions of IRAK4; early clinical signals in atopic dermatitis are promising
→Platform has multiple applications across oncology and immunology — Kymera's PEGASUS platform applies to hundreds of disease-relevant target proteins; the company is building a pipeline of multiple degraders across therapeutic areas; platform biotech companies command higher valuations when the technology's versatility is demonstrated

Risks to watch — RVMD

→Clinical-stage binary risk — all clinical-stage biotech companies face the risk of clinical trial failure; RVMD has no approved products; if RMC-6236 or other programs fail in later-stage trials, the stock would face severe declines
→Competitive landscape in KRAS inhibitors is intensifying — Amgen's Sotorasib and BMS's Adagrasib are approved; Eli Lilly acquired Mirati to deepen KRAS investment; Novartis has KRAS programs; competition from larger pharmaceutical companies with more resources is significant
→Combination partner selection and clinical execution for multi-drug trials adds complexity — KRAS-mutant cancers often have adaptive resistance to single-agent KRAS inhibitors; optimal outcomes may require combination therapy; choosing the right combination partner and designing combination trials adds complexity and cost

Risks to watch — KYMR

→PROTACs face drug delivery and ADME challenges unique to the technology — PROTACs are larger molecules than typical small molecule drugs; oral bioavailability (absorption from the gastrointestinal tract), tissue distribution, and metabolic stability of PROTAC molecules can be challenging; drug delivery is a significant technical risk for the platform
→Competitive pressure from other TPD companies — C4 Therapeutics, Arvinas, Nurix, and large pharma companies (Pfizer, Novartis, BMS) all have active PROTAC/degrader programs; if a competitor demonstrates stronger efficacy or first achieves regulatory approval in Kymera's target indications, Kymera's franchise value could be significantly reduced
→Platform risk — if PROTACs prove more difficult to develop as drugs than anticipated, the entire platform biotech thesis fails regardless of target biology quality

Frequently asked questions

RAS biology: RAS proteins (KRAS, NRAS, HRAS) are small GTPase signaling proteins that act as molecular switches — when RAS binds GTP (guanosine triphosphate), it is 'ON' and activates downstream signaling pathways (RAF-MEK-ERK, PI3K-AKT) that drive cell growth and division; when RAS hydrolyzes GTP to GDP, it turns 'OFF'; in normal cells, this on-off cycling is tightly regulated. Why RAS mutations cause cancer: mutations in RAS (most commonly KRAS G12C, G12D, G12V, and Q61H mutations) permanently lock RAS in the 'ON' state — the mutant RAS cannot hydrolyze GTP to GDP, remaining constitutively active; this drives continuous cell proliferation regardless of growth factor signals; this is a fundamental driver of approximately 25-30% of all human cancers. Why RAS was undruggable: for 35+ years after RAS was identified as an oncogene, drug developers could not target it; traditional drug design requires finding a binding site (pocket) on the protein surface large enough to fit a drug molecule; KRAS's surface is unusually smooth with no obvious deep binding pockets; the GTP/GDP binding site (the active site) binds GTP with picomolar affinity — no drug molecule can compete with GTP's binding affinity; the scientific community largely gave up on direct RAS inhibition. The breakthrough: the KRAS G12C mutation creates a unique covalent bond formation opportunity — a cysteine amino acid at position 12 can react irreversibly with specially designed covalent inhibitors in a pocket that only opens when KRAS is in the GDP-bound 'OFF' state; Amgen discovered this in the 2010s, leading to Sotorasib (Lumakras, 2021) — the first approved KRAS inhibitor.

AI Prediction SignalNext 5 trading days

Members only

RVMD

+2.8%BUY

KYMR

+1.1%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

More comparisons